Yahoo
Swiss - Delayed Quote CHF

Ypsomed Holding AG (YPSN.SW)

395.80 -11.00 (-2.70%)
At close: September 4 at 5:31:48 PM GMT+2
Chart Range Bar
Loading chart for YPSN.SW
  • Previous Close 406.80
  • Open 405.80
  • Bid 390.00 x --
  • Ask --
  • Day's Range 392.80 - 407.00
  • 52 Week Range 260.50 - 419.50
  • Volume 19,199
  • Avg. Volume 12,666
  • Market Cap (intraday) 5.204B
  • Beta (5Y Monthly) 0.77
  • PE Ratio (TTM) 24.27
  • EPS (TTM) 16.31
  • Earnings Date Nov 11, 2026
  • Forward Dividend & Yield 4.40 (1.08%)
  • Ex-Dividend Date Jul 3, 2026
  • 1y Target Est 398.38

Ypsomed Holding AG, together with its subsidiaries, develops, manufactures, and sells injection and infusion systems for safe and simple self-medication in Switzerland, Europe, North America, and internationally. The company offers various injection systems, such as pen injectors, auto-injectors, and wearable injectors, as well as other related services. It offers contract manufacturing of infusion sets and reservoirs. The company markets its products to hospitals, doctors, pharmacies and patients via subsidiaries and distributors. Ypsomed Holding AG was founded in 1984 and is headquartered in Burgdorf, Switzerland.

www.ypsomed.com

2,025

Full Time Employees

March 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 9/4/2026, which may include dividends or other distributions. Benchmark is MSCI WORLD (^990100-USD-STRD) .

YTD Return

YPSN.SW
22.16%
MSCI WORLD (^990100-USD-STRD)
11.86%

1-Year Return

YPSN.SW
2.09%
MSCI WORLD (^990100-USD-STRD)
19.91%

3-Year Return

YPSN.SW
61.93%
MSCI WORLD (^990100-USD-STRD)
0.00%

5-Year Return

YPSN.SW
178.73%
MSCI WORLD (^990100-USD-STRD)
57.61%

Analyst Insights

View More

Analyst Price Targets

280.00 Low
398.38 Average
395.80 Current
480.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (5yr expected)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    30.36%

  • Return on Assets (ttm)

    12.36%

  • Return on Equity (ttm)

    31.09%

  • Revenue (ttm)

    730.98M

  • Net Income Avi to Common (ttm)

    221.93M

  • Diluted EPS (ttm)

    16.31

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    28.56M

  • Total Debt/Equity (mrq)

    34.86%

  • Levered Free Cash Flow (ttm)

    -57.27M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: